SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* PATIENCE JOHN (Last) (First) (Middle) 919 WEST DILLON RD (Street) LOUISVILLE CO 80027 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol BIODESIX INC [ BDSX ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner Officer (give title below) X Other (specify below) Chairman
	3. Date of Earliest Transaction (Month/Day/Year) 05/21/2024
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/23/2024		M		217,400	A	(1)	4,829,611	I	By John Patience Living Trust dated 7/23/1993(2)
Common Stock								337,926	D
Common Stock								2,078,298	I	By Patience Enterprises LP(3)
Common Stock								52,988	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(4)	05/21/2024		A		46,686		(5)	(5)	Common Stock	46,686	$0	46,686	D
Stock Options (Right to Buy)	$1.57	05/21/2024		A		37,050		(6)	05/20/2034	Common Stock	37,050	$0	37,050	D
Series A Non-Voting Convertible Preferred Stock	(1)	05/23/2024		M			5,435	(1)	(1)	Common Stock	217,400	$0	0	I	By John Patience Living Trust dated 7/23/1993(2)

Explanation of Responses:

1. The Issuer's stockholders approved the conversion of shares of the Issuer's Series A Non-Voting Convertible Preferred Stock ("Preferred Stock") into shares of the Issuer's common stock ("Common Stock") at its 2024 annual meeting of stockholders held on May 21, 2024, after which each share of Preferred Stock automatically converted into 40 shares of Common Stock on May 23, 2024.

2. The Reporting Person is the sole trustee of John Patience Living Trust (July 23, 1993).

3. The Reporting Person is the sole general partner of Patience Enterprises LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

4. Each restricted stock unit (the "RSU") represents a contingent right to receive one share of Common Stock.

5. These RSUs will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. In the event the Reporting Person's continued service on the Board terminates other than for cause, these RSUs will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period.

6. This option will vest in full on March 31, 2025, generally subject to the Reporting Person's continued service with the Issuer. In the event the Reporting Person's continued service on the Board terminates other than for cause, this option will vest on a prorated basis based on the number of full months of service the Reporting Person completed during the applicable vesting period.

	/s/ Robin H. Cowie as Attorney-in-Fact for John Patience	05/23/2024
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.